Nyxoah to Host Investor Day in New York on July 8, 2026
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device
Inspire Medical: Sleeping Giant Awakens The OSA Implant Market, Initiating With A Buy
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
ICR Hosts ProSomnus CEO Len Liptak on the Welcome to the Arena Podcast
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
Oklahoma Sheriffs’ Association suspends three officials after recordings
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023